Multicenter cooperative observational study of idiopathic pulmonary fibrosis with non-small cell lung cancer

Table 1 Patient characteristics

No. of patients	17
Age (yr)
Median	65
Range	43-74
Sex
Male	16
Female	1
Performance status
0	6
1	11
Stage at enrollment
IIIA	2
IIIB	5
IV	10
Histology
Adenocarcinoma	11
Squamous cell carcinoma	5
Non-small cell carcinoma	1
Smoking status
Smoker	16
Non-smoker	1

Table 2 Main toxicities of chemotherapy

	Grade				Grade
	1	2	3	4	3-4 (%)
Leukopenia	3	8	2	1	19
Neutropenia1	0	1	8	6	88
Febrile neutropenia	0	0	1	0	6
Anemia2	5	2	3	0	19
Thrombocytopenia	8	3	0	0	0
Neuropathy	8	6	0	0	0
Myalgia	2	0	0	0	0
Anorexia	2	3	0	0	0
AST/ALT elevation	3	3	0	0	0

¹Seven patients received granulocyte colony-stimulating factors (75 or 100 μg);

²One patient with grade 3 anemia required a bloo d transfusion.

Table 3 First-line chemotherapy

Tumor response	CT group (n = 16)
Complete response	0
Partial response	6
Stable disease	5
Progressive disease	5
Response rate	38%
(95%CI)	(15%-65%)

CT: Chemotherapy.

Table 4 Cases of acute exacerbation of idiopathic pulmonary fibrosis

	Period (d)
	From registry (last chemotherapy) to AE-IPF	From AE-IPF to death
A group (n =1)	136	66
B group (n =16)
Case 1 CBDCA/PTX 2 cycles	56 (27)	20
Case 2 CBDCA/PTX 2 cycles	77 (47)	16
Case 3 CBDCA/PTX 3 cycles	124 (101)	6
Case 4 CBDCA/PTX 3 cycles	317 (249)	24
Case 5 CBDCA/PTX 3 cycles
→ 2nd line PEM 1 cycle	83 (12)	18
Case 6 CBDCA/PTX 3 cycles
→ 2nd line PEM 4 cycles	583 (14)	8

AE: Acute exacerbation; IPF: Idiopathic pulmonary fibrosis; CBDCA: Carboplatin; PTX: Plus paclitaxel; PEM: Pemetrexed; DOC: Docetaxel.

Table 5 Pretreatment parameters based on the presence or absence of an acute exacerbation of idiopathic pulmonary fibrosis

	AE-IPF		P1
	+ (n = 7)	- (n = 10)
CRP (mg/dL)	0.51 (0.14-15.0)	3.43 (0.15-11.1)	0.77
LDH (IU/L)	191 (132-399)	205 (163-969)	0.73
KL-6 (U/mL)	603 (285-1373)	683 (381-2340)	0.56
SP-D (ng/dL)	88.3 (69.1-457)	101 (58.9-139)	1.00
PaO2 (mmHg)	77.1 (75.0-85.3)	76.8 (69.0-91.7)	0.78
%VC (%)	100.1 (83.7-131.1)	83.6 (68.0-115.7)	0.07
%DLCO (%)	58.9 (49.5-78.3)	65.3 (58.3-92.2)	0.25
6MWT: Minimum SpO2 (%)	93 (90-98)	93 (90-95)	0.77

Values are expressed as the median (range). ¹Wilcoxon rank-sum test. AE-IPF: Acute exacerbation of idiopathic pulmonary fibrosis; 6MWT: 6-min walk test.